Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Study of B001 in CD20+ B-cell Non-Hodgkin's Lymphoma
NCT03332121Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Mar 2018
- Primary completion
- Nov 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B001 in B-cell non-Hodgkin lymphoma, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoint: Safety of B001 as assessed by adverse reactions and events at 42 days. Started Mar 2018; status: completed.
02
Drugs
B001
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03332121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332121.